Cargando…

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE

INTRODUCTION: Randomised controlled trials (RCTs) may use surrogate endpoints as substitutes and predictors of patient-relevant/participant-relevant final outcomes (eg, survival, health-related quality of life). Translation of effects measured on a surrogate endpoint into health benefits for patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manyara, Anthony Muchai, Davies, Philippa, Stewart, Derek, Weir, Christopher J, Young, Amber, Butcher, Nancy J, Bujkiewicz, Sylwia, Chan, An-Wen, Collins, Gary S, Dawoud, Dalia, Offringa, Martin, Ouwens, Mario, Ross, Joseph S, Taylor, Rod S, Ciani, Oriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Research Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557267/ https://www.ncbi.nlm.nih.gov/pubmed/36220321 http://dx.doi.org/10.1136/bmjopen-2022-064304

Ejemplares similares

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

A call for better reporting of trials using surrogate primary endpoints
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
por: Ciani, Oriana, et al.
Publicado: (2023)

Protocol of the CONSORT and SPIRIT Extension for multicenter clinical trials
por: Zhang, Xuan, et al.
Publicado: (2023)

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence
por: Ciani, Oriana, et al.
Publicado: (2022)

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study
por: Solovyeva, Olga, et al.
Publicado: (2023)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation
por: Wheaton, Lorna, et al.
Publicado: (2023)

Bayesian hierarchical meta‐analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data
por: Papanikos, Tasos, et al.
Publicado: (2020)

SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol
por: Espinasse, Aude, et al.
Publicado: (2023)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Reporting guidelines for clinical trials of artificial intelligence interventions: the SPIRIT-AI and CONSORT-AI guidelines
por: Ibrahim, Hussein, et al.
Publicado: (2021)

The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
por: Poad, Heather, et al.
Publicado: (2022)

Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
por: Ciani, Oriana, et al.
Publicado: (2021)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Treatment effect bias in randomised controlled trials using surrogate outcomes: a preliminary cohort study analysis
por: Ciani, Oriana, et al.
Publicado: (2011)

IJD(®): Consorting with CONSORT 2010
por: Panda, Saumya, et al.
Publicado: (2013)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Implications of the artificial intelligence extensions to the guidelines for consolidated standards of reporting trials and for standard protocol item recommendations for interventional trials (the CONSORT-AI and SPIRIT-AI extensions)
por: Solebo, Ameenat Lola, et al.
Publicado: (2020)

Use of copula to model within‐study association in bivariate meta‐analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation
por: Papanikos, Tasos, et al.
Publicado: (2022)

Surrogates are just surrogates, but helpful just the same
por: Fabian, Carol
Publicado: (2007)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project
por: Eastell, Richard, et al.
Publicado: (2021)

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_eigedjfraued3r34hn2um32fl4